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Objective: The objective of the study was to describe our early experience with a comprehensive uterine fibroid
center and report our results in women seeking a second opinion for management of symptomatic uterine
leiomyoma.
Methods: We performed a HIPAA-complaint, IRB-approved retrospective study of women seeking second opinion
for management of uterine fibroids at our multidisciplinary fibroid treatment center in a tertiary care facility from
July 2008 to August 2011. After a review of patients’ history, physical examination, and magnetic resonance imaging
(MRI) findings, treatment options were discussed which included conservative management, uterine-preserving
options, and hysterectomy. We performed Fisher’s exact test for categorical variables between the cohort that did
or did not undergo a uterine-preserving treatment. Differences were considered significant at p < 0.05.
Results: The mean age of the 205 patient study cohort was 43.8 years (SD 7.5). One hundred sixty-two (79.0%)
patients had no prior therapy. Based on MRI, one or more fibroids were detected in 178/205 (86.8%), adenomyosis
in 8/205 (3.9%), and a combination of fibroid and nonfibroid condition (i.e., adenomyosis, endometrial polyp) in
18/205 (8.8%). In those who desired to transition their care to our institution (n = 109), 85 patients underwent 90
interventions: 39 MRgFUS (magnetic resonance-guided high-intensity focused ultrasound surgery), 14 UAE (uterine
artery embolization), 25 myomectomies, 8 hysterectomies, 3 polypectomies, and 1 endometrial ablation. Five
patients had two procedures. Intramural and subserosal fibroids were most commonly treated with MRgFUS
followed by myomectomy and then UAE; in contrast, pedunculated fibroids were frequently managed with
myomectomy.
Conclusions: Multidisciplinary fibroid evaluation may facilitate the increase use of less invasive options over
hysterectomy for symptomatic fibroid treatment.
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Uterine fibroids, or leiomyomas, are benign growths of
the uterine smooth muscle estimated to occur in up to
20% to 35% of all reproductive-age women, and by 50 years
of age, prevalence increases to 70% among white and 80%
among African-American ancestry [1,2]. Up to 30% of
women with uterine leiomyoma are symptomatic [3] with
abnormal uterine bleeding and/or bulk symptoms such as* Correspondence: ntan@mednet.ucla.edu
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stated.pressure, fullness, urinary symptoms, and increased ab-
dominal girth. These symptoms can reduce quality of life
in addition to impacting fertility and pregnancy [4,5].
Leiomyoma-related signs and symptoms may be influ-
enced by their location, size, and number [6,7].
The available treatment options for women with symp-
tomatic uterine fibroids include surgical techniques such
as hysteroscopic myomectomy, laparoscopic myomectomy,
robotic-assisted laparoscopy, minimally invasive options
such as uterine artery embolization (UAE), laparoscopic or
percutaneous radiofrequency ablation, and noninvasive ab-
lative therapies such as magnetic resonance-guided high-. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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ous factors including patient preference, desire for future
pregnancy, symptoms, and fibroid number, size, and loca-
tion are carefully assessed in deciding treatment options.
Despite the proliferation of uterine leiomyoma treat-
ment options in the USA, over 60% of symptomatic
uterine leiomyomas are treated surgically with up to
70% undergoing hysterectomy [5]. Over US$2 billion is
spent annually for leiomyoma-related care, with the ma-
jority of the cost related to inpatient hospital stay after
surgery [8,9]. There is limited understanding to explain
the current treatment patterns of uterine fibroids [5]. It
is likely that a complex set of sociodemographic, eco-
nomic, referral pattern as well as availability of resources
contribute to these trends. In standard of care, women
are unlikely to receive a comprehensive set of options
regarding treatments for fibroid-related symptoms and
are usually offered only a narrow range of treatments
based on single physician preference.
In a variety of diseases, a multidisciplinary approach
improves patient and disease outcomes with reduction
in adverse events compared to traditional standard of
care [10-13]. These demonstrated improvements in pa-
tient care led us to create a multidisciplinary center for
patients with uterine fibroids in 2008. The aim of this
study was to describe the clinical outcome of our multi-
disciplinary fibroid center as related to magnetic reson-
ance imaging (MRI) findings and treatment elected by




This study was approved by the UCLA Office of Human
Research Protection Program and is compliant with
HIPAA. A single cohort observational study of all pa-
tients consecutively evaluated at our multidisciplinary fi-
broid center at a major tertiary referral facility from 1
July 2008 to 31 August 2011.
Multidisciplinary fibroid center
At our multidisciplinary fibroid center, each patient with
suspected fibroid-related symptoms underwent consult-
ation by both a radiologist and gynecologist. A variety of
other physicians including reproductive endocrinolo-
gists, internists, and subspecialists acted as consultants
to the multidisciplinary fibroid center as necessary. All
physicians were employees salaried by the university
academic medical group but billed separately for any
given consultation. Women were either referred to the
multidisciplinary fibroid center by their gynecologists
or primary care physicians or self-referred by online
search for uterine fibroid treatment for second or third
opinions. Other referrals were from friends, family, radioadvertisements, and fibroid treatment features on televi-
sion talk shows. Women with prior imaging were encour-
aged to mail their studies to our center for review. In
patients with prior documented ultrasound (US) imaging
positive for uterine fibroids or if the consultation was for a
second opinion, a contrast-enhanced pelvic MRI was per-
formed to better characterize the number, size, and pos-
ition of the fibroids.
Clinic visits included sequential 30-min consultations
with a gynecologist specializing in fibroid-related prob-
lems and a radiologist specializing in pelvic imaging and
intervention. Each physician independently obtained a
comprehensive gynecological history. Fibroid-specific
history obtained from the women included the present-
ing symptoms (bulk vs. bleeding), severity of the symp-
toms, prior treatments, and the women’s desire for
future fertility. A routine physical exam of the heart,
lungs, and abdomen and pelvis was typically performed
by the radiologist and was supplemented by an inde-
pendent formal pelvic examination performed by the
gynecologist. The contrast-enhanced pelvic MR scan
was reviewed concomitantly by both the gynecologist
and interventional radiologist to determine the number,
size, location of the fibroid, juxtaposition to the endo-
metrial cavity, and relationship to surrounding pelvic or-
gans. The pelvic MR scan was also used to subtype each
fibroid (classical, hypercellular, or degenerated) to help
improve the triage of these lesions. Classical fibroids
were of low signal intensity on T2-weighted imaging and
enhanced avidly on dynamic contrast-enhanced T1-
weighted imaging and were amenable to treatment by all
modalities. Hypercellular fibroids had high T2 signal and
enhanced avidly on dynamic contrast-enhanced T1-
weighted imaging and responded poorly to MRgFUS.
Lesions that lack enhancement are thought to have under-
gone either red or cystic degeneration and would not
benefit from either uterine embolization or MRgFUS.
Information from the history and physical examin-
ation, MRI, and patients’ treatment request were used to
offer one or more treatment options to each woman.
The ultimate treatment decision was made in partner-
ship with the patient with respect to her preference. If a
nonfibroid condition was diagnosed, further work-up
was then performed on a case-by-case basis by the gyne-
cologists (see Figure 1).
Magnetic resonance imaging
MRI of the pelvis was performed in prone position with
an external pelvic phased array coil for reception using
either 1.5-T (Sonata, Avanto, Siemens Medical Solutions,
Erlangen, Germany or Horizon LX; GE Medical Systems,
Milwaukee, WI, USA) or 3-T scanners (Trio, Vario,
Siemens Medical Solutions, Erlangen, Germany). Women
were scanned in the prone position to most closely mimic
Figure 1 The flowchart of the process patients take. It is from the time point they learn about the center to the time when they are seen by
the center’s providers.
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the pelvis include the following sequences: axial T1 2D
spoiled gradient-recalled echo dual-echo (FMPSGPR,
GE Healthcare, Milwaukee, WI, USA or FLASH 2D,
Siemens Medical Systems, Erlangen, Germany), axial
3D T1 with fat saturation (liver acquisition with volume
acceleration (LAVA), gradient echo (GE), or volumetric
interpolated breath-hold examination (VIBE); Siemens),
axial 2D single-shot T2 (SSFSE, GE, or HASTE; Siemens),
axial, coronal, oblique axial, and coronal of uterus multi-
shot T2 (FLARE, GE, or RESTORE; Siemens). After intra-
venous power injection of 0.1 mmol/kg of gadolinium
DTPA (Magnevist, Bayer Healthcare, Berlin, Germany) at
2 cm3/s, dynamic sagittal 3D VIBE with fat saturation im-
aging was performed at 30, 60, 90, and 120 s. Coronal and
axial 3D VIBEs with fat saturation were also obtained at
180 and 300 s, respectively. One of two fellowship-trained
abdominal imaging radiologists with 14 and 19 years of
experience in pelvic MR interpretation reviewed all the
studies on a commercially available workstation with
high-resolution monitors (Centricity 2.0, GE Healthcare).
For each fibroid, the radiologists determine the size, num-
ber and location, T2 signal, presence of adenomyosis or
endometrial polyps, relative enhancement after intraven-
ous gadolinium, and the dominant arterial supply to the
uterus. The adnexa and cervix were evaluated to exclude
incidental masses.
Treatment algorithm
In the multidisciplinary fibroid center, treatment was
stratified into medical therapy, MRgFUS, UAE, hystero-
scopic resection, myomectomy (laparoscopic, robotic, or
open), and hysterectomy. Medical therapy, such as oralcontraceptive pills, were used as first-line treatment for
women with abnormal uterine bleeding, but women who
were refractory to conservative treatment can elect to
undergo any of the appropriate therapies. Gonadotropin-
releasing hormone (GnRH) was also used to manage ab-
normal uterine bleeding or to reduce the fibroid size prior
to myomectomy or MRgFUS.
MRgFUS is a noninvasive treatment option most indi-
cated in women with a single dominant, classical, non-
pedunculated, nondegenerated fibroid less than 10 cm in
size and is offered to women who desired future fertility.
On a case-by-case scenario, women with more than one
fibroid may be offered MRgFUS. Women with hypercel-
lular or degenerated fibroids were considered poor can-
didates for MRgFUS.
UAE was discussed as a treatment option primarily in
women with intermediate-sized (8–10 cm) to large-sized
(>10 cm), nonpedunculated, classical or hypercellular,
nondegenerated fibroids (>10 cm) or with multiple fi-
broids (>5). UAE was typically not offered to women
who desired future fertility.
With respect to women who chose surgery but desired
future fertility or in women with large pedunculated fi-
broid, myomectomy (robotic-assisted laparoscopic ap-
proach, hysteroscopic, or open) was the recommended
therapy. Desire for future fertility precluded UAE and
hysterectomy, but not myomectomy or MRgFUS.
Hysteroscopic myomectomy was recommended for
women with small (<4 cm) intracavitary leiomyomas, es-
pecially if they are pedunculated (type 0) or >50% of the
circumference is bulging into the endometrium (type 1).
Open or robotic-assisted laparoscopic or laparoscopic hys-
terectomy was recommended when patients had symptom
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Table 1 for the summary of inclusion and exclusion cri-
teria for various treatment therapies.
Data
Patient demographics, clinical history, MRI findings, treat-
ment eligibility, and follow-up management outcomes
were retrieved from the electronic medical records and re-
corded in a database by a single medical provider.
Statistical analysis
Mean and standard deviation were determined for age
and number of fibroids; median and range were mea-
sured for fibroid size. We performed Fisher’s exact test
for categorical variables between the cohort that did or
did not undergo uterine-preserving treatments. All ana-
lyses were done using the statistical software STATA/SE
11.2 (College Station, TX, USA), and statistics were con-




The study cohort consisted of 205 patients with a mean
age of 43.8 years (standard deviation (SD) 7.5). Nearly all
patients had received a diagnosis of uterine fibroids from
outside clinics based on physical exam and/or ultra-
sound, and most had been offered hysterectomy from
outside facilities for treatment. The most common pre-
senting complaints were bleeding symptoms (41.9%),
bulk symptoms (25.6%) or combination bulk and bleed-
ing symptoms (12.7%). The remainder of patients pre-
sented with a variety of other symptoms unrelated to
either bulk or bleeding (e.g., dyspareunia, abdominal pain,
back pain, urinary incontinence, and infertility; 20.0%).
One hundred sixty-two (79.0%) patients had not had prior
therapy. In 43/205 (21.0%) patients with a history of priorTable 1 Summary of inclusion and exclusion criteria for vario
Treatment Inclusion criter
MRgFUS • Single, domina
• Multiple (≤5 fib
• Desires fertility
UAE • Intermediate (5
(>10 cm) fibroi
• Multiple >5 fib
Myomectomy (robotic-assisted, hysteroscopic, or open) • Desires fertility
• Small (<4 cm)
• Pedunculated
Hysterectomy • Failed first-linetreatment, 27/43 (62.8%) had oral contraceptive pill or
gonadotropin-releasing hormone agonist, 9/43 (20.9%)
had myomectomy, 2/43 (4.6%) had endometrial ablation,
and 5/43 (11.6%) had prior UAE.Treatment recommendations
Treatment recommendations were made jointly by the
radiologist and gynecologist based on the patients’ symp-
toms, physical exam findings, MRI findings, and prefer-
ences. Although all patients sought therapy for presumed
uterine fibroids based on a previous diagnosis, up to
13.2% had either a combination of fibroid and nonfibroid
conditions (i.e., adenomyosis, endometrial polyp) in 18/
205 (8.8%) or adenomyosis in 8/205 (3.9%) patients
(Figure 2). Based on MRI, fibroids were detected on
MRI in 178/205 (86.8%) patients. The majority of pa-
tients were eligible for treatment with medical or
uterine-preserving therapies to manage their symptoms
(Figure 2). Hysterectomy was recommended for 9/205
(4.4%) patients (Table 2).Treatment provided
Of the 205 patients in the study cohort, 109 (53.2%)
elected to transfer their care to our institution. Medical
therapy or no further treatment was recommended for
24/109 patients (22.0%; Figure 3). A total of 85/109 pa-
tients (77.9%) underwent 90 procedures, and 8/109 pa-
tients (7.3%) underwent hysterectomy (Figure 3). The
distribution of the treatment type provided to the patients
who had follow-up care with our institution was based on
characterization and localization of uterine pathology by
MRI (p ≤ 0.01; Table 3). The median size and number of
fibroids among 85 patients who underwent 90 procedures
were reported in Table 4. Of the myomectomy cohort, 15/
25 (60%) patients were managed with minimally invasive
surgical procedures (Table 4).us treatment therapies
ia Exclusion criteria
nt if <10 cm • Degenerated or pedunculated
roids) if <5 cm • Hyperintense signal on T2-weighted
(hypercellular) MRI
–10 cm) to large
ds
• Degenerated or pedunculated
roids • Desires fertility (relative contraindication)
• Poor surgical candidate (significant comorbidities)
intracavitary
treatment • Poor surgical candidate (significant comorbidities)
• Desires fertility
Figure 2 General treatment algorithm and distribution of recommendations. General treatment algorithm for women presenting to the
comprehensive fibroid center and the distribution of recommendations made based on patients’ symptoms and MRI findings. Asterisk denotes
nonfibroid conditions existing concurrently with fibroids: adenomyosis (n = 13), ovarian cyst endometrioma (n = 2), endometrial polyp (n = 3).
Section sign denotes that one patient had urinary retention; the other patient had imaging findings that did not correspond to the patient’s
pelvic pain. Dagger denotes that hysterosonogram was recommended to evaluate for a possible endometrial polyp. Recommendations to be
evaluated at the fibroid center were made when feasible for the patient.
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tient 1, with pressure symptoms and abnormal uterine
bleeding who on MRI had an intracavitary lesion and
multiple intramural fibroids, had planned a combination
of MRgFUS for the intramural lesions and hysteroscopic
myomectomy for the intracavitary fibroids. Patient 2 had
pressure symptoms and had a 10-cm pedunculated fi-
broid and a 5-cm intramural fibroid on MRI and under-
went a combination of MRgFUS for the intramural fibroid
and robotic-assisted laparoscopic myomectomy for the pe-
dunculated fibroid. Patient 3 who presented with pressure
and bleeding symptoms had a 10-cm intramural fibroid
abutting the endometrial stripe on MRI and underwentTable 2 Reasons for the recommended hysterectomy in nine
Patient Clinical and imaging findings
1 17-cm fibroid
2 >7 fibroids, 3–5 cm which increase in size causing dyspareu
3 21-cm posterior exophytic fibroid
4 Multiple fibroids; largest is 7 cm with concomitant adenomy
5 Multiple fibroids; largest is 10 cm
6 Multiple fibroids; largest is 4 cm with concomitant adenomy
7 Patient s/p UAE with peripherally calcified 6-cm fibroid
8 7-cm fibroid extending to the cervix
9 Multiple 6–7-cm fibroidsMRgFUS with bleeding symptom improvement but had
persistent bulk symptoms and subsequently underwent
open myomectomy. Patient 4 presented with urinary fre-
quency and had a 10-cm submucosal fibroid on MRI; she
elected and underwent MRgFUS with transient symptom-
atic improvement. Subsequently, the patient underwent
open myomectomy due to symptom recurrence. Patient 5
had bulk symptoms and had multiple intramural fibroids.
Though not ideal for MRgFUS, this patient was directive
about receiving this modality and after explicit risk/benefit
counseling underwent MRgFUS. She did not have suffi-
cient improvement in her symptoms and subsequently
had UAE with symptom relief.patients
Follow-up care
Open supracervical hysterectomy. Patient had endometriosis
seen intraoperatively which was cauterized
nia Open supracervical hysterectomy
Open supracervical hysterectomy
osis Robotic-assisted laparoscopic supracervical hysterectomy





Figure 3 Treatment provided to women who changed to our institution. In women who changed their care to our institution after initial
consultation, the following describes the treatment provided to the patients based on their preferences, symptoms, and MRI findings.
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In this study, we have shown that a multidisciplinary fi-
broid center model is feasible and provides patients with
a full range of treatment options including alternative
therapy. On contrast-enhanced MRI, 13.2% of the pa-
tients with prior outside diagnosis of uterine leiomyoma
had other pathologies on MRI (i.e., adenomyosis and
endometrial polyp). The distribution of the procedureTable 3 Distribution of interventions provided based on char
in 88 women
Diagnosis MRgFUS (n = 39) UAE
Fibroids (subtypes) Intramural/subserosal (n = 60) 31
Submucosal (n = 17) 7
Intracavitary (n = 12) 4
Exophytic (n = 7) 3
Pedunculateda (n = 11) 0
Cervical (n = 1) 0
Others Adenomyosis (n = 9) 4
Endometrial polyp (n = 3)b 0
These women underwent nonmedical treatment, while women electing expectant
aThough UAE is not the standard treatment for pedunculated fibroids, each of the t
Both patients had a nondominant small (<2 cm) pedunculated fibroid seen on MR.
bAll three patients with endometrial polyps underwent polypectomy.
cOpen/laparoscopic-assisted robotic myomectomy.
dFisher’s exact test was used.type depended on the fibroid size, MR-based subtype
(classical, hypercellular or degenerated), location, and
concomitant existing uterine pathologies. In our cohort,
most patients qualified for uterine-preserving treatment;
we suggested hysterectomy in 4.4% of our patients al-
though the majority had been offered hysterectomy at
other facilities. Of patients who changed care to our in-
stitution, 77.9% were treated with either an image-acterization and localization of uterine pathology by MRI





ablation (n = 1)
p value
9 17 3 0 <0.01d
3 3 3 1
3 5 0 0
1 2 1 0
2 7 0 0
0 1 0 0
2 1 2 0 -
0 0 0 0 -
management or medical therapy were not included in this table.
wo patients who underwent uncomplicated UAE had multiple (>10) fibroids.
Table 4 Size and number of fibroids in 85 patients who underwent 90 procedures
Procedures (total) Age Fibroid size (cm) Number of fibroids Miscellaneous
Mean (SD) Median (range) Mean (SD)
MRgFUS (n = 39) 40.4 (9.5) 7.3 (5–10) 2.6 (2.9) Two patients had MRgFUS adenomyosis
UAE (n = 14) 47.1 (4.7) 7.8 (6.2–8.5) 2.2 (1.1) Two patients had UAE for isolated adenomyoma
Two patients were with hypercellular intramural >8 cm fibroids
Four patients were with >5 fibroids
Myomectomy (n = 25) 43.2(6.6) 8.0 (5.4–11) 2.9 (2.2) Approach: 11 hysteroscopic, 10 open, 2 robotic, 2 laparoscopic
myomectomies
Hysterectomy (n = 8) 46.0 (5.7) 9.5 (7.8–14.0) 4 (3.7) Two patients were with isolated adenomyoma
Approach: two laparoscopic hysterectomies
Polypectomy (n = 3) - - -
Endometrial ablation (n = 1) 2.2 cm 1 -
Five patients had two procedures.
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sound was the most common procedure performed
followed by myomectomy.
Pron [14] questioned why adoption of newer approaches
for treatment of uterine fibroids was lagging despite evi-
dence supporting the safety and efficacy of minimally in-
vasive therapies. She argued that the issue of low adoption
was due to the behavioral and practice patterns of clini-
cians who may be uncomfortable or unfamiliar with non-
surgical options performed by other specialties. Even
among gynecologists, adoption of newer, minimally inva-
sive, uterine sparing techniques may be variable. In a
study reviewing clinical experience from the UK [15], a
survey of gynecologists reported that 11% performed lap-
aroscopic myomectomy and 43% performed hysteroscopic
myomectomy. The author argued that the low rate of
adoption of the laparoscopic approach was likely due to
lack of training, the nonavailability of instruments, as well
as worries about prolonged operative time compared to a
hysteroscopic approach. Further, although 51% of gynecol-
ogists had access to UAE, the median number of patients
referred to UAE was only five per year [15]. The results af-
firmed the underutilization of minimally invasive surgery
and nonsurgical options for treatment of uterine fibroids.
The underutilization of minimally invasive options was
also reported in a study in the USA, where of the 42% of
women with fibroids who underwent an intervention, 78%
of these women underwent hysterectomy with only 10%
undergoing myomectomy, 3% undergoing endometrial ab-
lation, and 4% undergoing multiple therapies [5].
We have shown that gynecologists and interventional
radiologists can successfully partner together to provide
women with fibroid-related symptoms the widest variety
of treatment options possible. In our multidisciplinary fi-
broid center, women seeking second opinion tended to
choose less invasive options for symptomatic fibroid
treatment favoring nonsurgical procedures followed bymyomectomy (Table 4). Among the myomectomy cohort,
60% were also managed using a laparoscopic, robotic, or
hysteroscopic approach over open myomectomy. The re-
sults suggest that in the setting of a multidisciplinary cen-
ter in women seeking second opinion, a less invasive
surgical option is preferred even for large or multiple
fibroids.
The discrepancy between distribution of treatments
among this study’s cohort and those reflecting the na-
tional trends may be due to how patients and clinicians
learned about emerging fibroid therapies. Ankem [16]
surveyed radiologists in Michigan to understand the
sources of information radiologists used to learn about
UAE. The results demonstrated that while national and
regional conferences were the initial source of informa-
tion for the early adopters, colleagues’ practice patterns
were the most important source of information for late
adopters. The study argued that work relations and com-
munication among clinicians was the most conducive
means for flow of information about UAE. An institution-
based practice as well as availability of appropriate
resources may explain why newer modalities were widely
accepted and used in our clinical practice.
Patients usually uncover information about nontradi-
tional and alternative fibroid therapies from internet
sources, and this may also explain why our cohort of pa-
tients elected the therapies they did. One study [17] in-
vestigated the information-seeking behavior of patients
with symptomatic fibroids, specifically in those who
learned about and underwent UAE. In this study, 40%
learned about UAE from their gynecologist and 60% be-
came aware of UAE through mass media, friends, or
family members. Our experience confirmed this result
since the vast majority of women were offered only hyster-
ectomy in the community. Additionally, women in this
study were asked to rate the helpfulness of an information
source in providing information that they needed. The
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helpful in providing information, followed by the internet,
then by gynecologists and other primary care doctors.
MRI is regarded as the definitive modality for uterine
fibroid imaging. Although initially expensive, it is the
most accurate and reproducible imaging method for de-
tecting, localizing, and characterizing leiomyoma [18,19]
Unlike US or CT, MRI can also characterize fibroid sub-
types, assess for fibroid degeneration, delineate the pres-
ence of gonadal arterial supply to individual fibroids (for
UAE planning), and uncover a range of coexisting path-
ologies such as adenomyosis, polyps, urethral diverticula,
and adnexal masses. [20] Thus, MRI enables a comprehen-
sive and objective noninvasive gynecological evaluation to
determine whether a patient undergoes laparoscopic myo-
mectomy, UAE, or MRgFUS. It provides an immediate
method of triage for a range of problems that often coexist
like adenomyosis and endometrial polyps, where in tandem
were detected in up to 13% of our cohort with outside US
diagnosis of fibroids. MRI has been proven superior to US
in diagnosing adenomyosis [21-23]. Although adenomyosis
may be treated with UFE, its role was still evolving, and
preoperative diagnosis was important for triage. Unlike
with US, MRI also enabled a confident diagnosis of de-
generating fibroids, which would not benefit from UAE
or MRgFUS. Similarly, MRI enabled a confident diag-
nosis of hypercellular fibroids which respond very
poorly to MRgFUS [24]. Thus, the European Society of
Human Reproduction and Embryology [25] endorsed
MRI as a second-line technique examination for exam-
ining morphologic and vascular features of leiomyoma
and for triaging treatment options as compared to US
primarily due to the higher expense of MRI.
We recognize that the use of MRI as the primary diag-
nostic tool at our center is not the standard of practice.
However, we feel that our practice is a specialized center
and that the patient population is unique compared to a
typical gynecology or primary care practice. Most
women came with known diagnosis of fibroids and came
to us seeking specific treatments not available to all
practices (i.e., MRgFUS). MRI allowed us to provide the
most comprehensive and accurate noninvasive diagnosis
to guide appropriate treatment recommendations during
multidisciplinary consultation. There has not been a trial
of cost-effectiveness of using MRI to triage women with
leiomyoma over US as the primary imaging modality.
However, Schwartz et al. [26] prospectively evaluated the
impact of MRI on treatment decisions for 69 consecu-
tive women scheduled to undergo gynecologic surgery
and effect on change in medical expense. The diagnosis
was changed in 53% of patients. Of this cohort, 81% had
a change in treatment; the most common change was
cancellation of surgery. Use of MRI resulted in overall
savings per patient. Moreover, Lin et al. demonstratedthat people are willing to undergo diagnostic radiology
exams—and are willing to pay more—to reduce un-
necessary, invasive medical procedures and overall
health costs [27].
There were several limitations to our study. One sig-
nificant potential source of bias was the self-referred na-
ture of our patient population. These women were
searching online for uterine-preserving options and
would likely choose uterine-preserving treatments, and
thus, the results should not be generalized to all patients.
Patients also likely came with a preconceived notion for
specific treatment, creating another source of selection
bias for the study cohort, and thus, the results may not
be applicable to the general population. Another bias
was in the socioeconomic status of our patients. In gen-
eral, our patient population had health insurance, and as
a result, outcomes and conclusions may not be represen-
tative of the general population across all socioeconomic
groups. Moreover, our medical center provided all com-
prehensive treatments, and as such, our findings may
not be applicable to community-based practices, which
may have limited access to certain treatment such as
MRgFUS, robotics, or UAE. We used MRI as the diag-
nostic study of choice which was not the standard prac-
tice. Therefore, we do not advocate MRI for initial
presentation and evaluation. However, in women seeking
a second opinion for prior diagnosis of uterine leio-
myoma at a comprehensive fibroid center, MRI allowed
us to provide efficient and definitive diagnosis to direct
the patient to appropriate treatments.
Despite the limitations, our study supported the feasi-
bility of establishing multidisciplinary fibroid centers to
address women with symptomatic fibroids. With in-
creasing access to the internet and utilization of social
media, patients will likely be the driving force to the
adoption of less invasive, less radical treatment alterna-
tives across all surgical fields including gynecology as
they learn about new and evolving treatment options. In
our patient population, most women were candidates for
uterine-preserving options and chose to undergo a min-
imally invasive uterine-preserving treatment.
Conclusions
Uterine fibroids had been managed by a single subspe-
cialist effectively, typically gynecologists. However, with
the advent of multiple therapeutic options for treatment
of symptomatic uterine fibroids which are performed by
different subspecialists, there is an increasing need for
crosstalk between multiple specialties to provide com-
prehensive options for women. Patients can then decide
for themselves which treatment is best suited for their
needs and wishes. In the USA, most women are man-
aged with surgical therapy, most commonly hysterec-
tomy. The reasons for this are likely multifactorial
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care. To overcome some of the barriers for patients, we
started a comprehensive fibroid center in collaboration
with gynecology and radiology, and we reported our early
experience with the center. Our results demonstrate that
patients undergo a wide range of therapy. However, there
is a significant preference towards uterine-preserving op-
tions. Of these, MR-guided focused ultrasound surgery
was the most commonly utilized procedure. Our findings
suggest that women desire minimally invasive therapies,
and joint effort between gynecology and radiology maybe
one option for institutions to improve access to most, if
not all, of the therapeutic options available for symptom-
atic uterine fibroids.
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